CRBP Stock — Corbus Pharmaceuticals Holdings Inc.: Cash, EV, Pipeline

What they do

Our pipeline is as follows: CRB-701 CRB-701 (SYS6002) is a novel clinical stage ADC that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of MMAE. In February 2023, the Company obtained a license from CSPC Megalith Biopharmaceutical Co.

Source: 10-K FY2025 via SEC EDGAR

Share price

$3.07

Market cap

$59.4M

Cash

$117.9M

Enterprise value

-$58.5M

Balance sheet

Cash	$117.9M
Debt	$0.0M
Net cash	$117.9M
Enterprise value	-$58.5M
Basic shares	15.9M shares
Fully diluted shares	20.3M shares
Fully diluted market cap	$62.4M
Cash per share	$7.42
Quarterly burn	$29.6M
Cash runway	4.0 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

15.9M

Pre-funded warrants

1.0M

Options

2.2M

RSUs

1.2M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

20.3M

Cap table as of 2026-06-30.

Price history

Loading CRBP daily closes…

Loading price history…

Next catalyst

CRB-601 monoclonal antibody · Dec 13, 2026 - Jan 24, 2027 in 5 wks · Phase 1/2 · Solid Tumor

Recently reported

CRB-913 Phase 1 Positive · 2026-09-14

CANYON-1

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 13, 2026 - Jan 24, 2027 in 5 wks	CRB-601 monoclonal antibody	Phase 1/2	Solid Tumor	—
GUIDEDEst. Feb 14, 2027 in 8 wks quarter midpoint	CRB-701 CRB-701 + Keytruda combination in first-line OPSCC (data)	Not disclosed	first-line OPSCC (data)	Q1 2027
Feb 27 - Apr 10 in 16 wks	CRB-701	Phase 1/2	Solid Tumor, Adult	—
Jan 12 - Feb 23 in 14 mo	CRB-701	Phase 3	Oropharyngeal Carcinoma (OPC)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

CRB-701

Phase 1 · Active Modality: antibody drug conjugate (ADC)

Aliases SYS6002

Target Nectin-4

Partnerships Licensed from CSPC Megalith Biopharmaceutical Co. Ltd. (Feb 2023); Corbus holds U.S., Canada, EU/EFTA, U.K., Australia rights. CSPC is investigating CRB-701 in a Phase 3 cervical cancer trial in China.

Indications

Second-line oropharyngeal squamous cell carcinoma (OPSCC) (Phase 1)
Cervical cancer (Phase 1)
Head and neck squamous cell carcinoma (HNSCC) (Phase 1)

Catalysts

— September 2026
— Q1 2027

Status note Next-generation ADC targeting Nectin-4 with MMAE payload. Phase 1/2 Western study (U.S. and Europe) in advanced Nectin-4-expressing solid tumors ongoing; dose expansion ongoing; PD-1 combination arm with Keytruda (pembrolizumab) began dosing Jun 2025. Fast Track: r/r metastatic cervical cancer (Dec 2024); recurrent/metastatic HNSCC previously treated with platinum + anti-PD(L)-1 (Sep 2025). FDA cleared registrational study TEMPO-1 in 2L OPSCC.

CRB-913

Phase 1 · Active Modality: small molecule (oral CB1 inverse agonist)

Target CB1 (cannabinoid receptor type 1)

Partnerships Licensed from Jenrin Discovery, LLC (Sep 2018); exclusive worldwide rights.

Indications

Obesity (Phase 1)

Catalysts

— September 2026

Status note Orally delivered, highly peripherally restricted cannabinoid type-1 (CB1) inverse agonist for obesity. Phase 1a SAD/MAD completed Dec 2025. Phase 1b dose-range finding study CANYON-1 (240 U.S. patients, 4 arms, 12 weeks treatment + 4 weeks follow-up) initiated Dec 2025; last patient completed last clinical visit Aug 2026.

CRB-601

Phase 1 · Terminated Modality: monoclonal antibody

Target αvβ8 integrin

Partnerships Licensed from The Regents of the University of California (May 2021); exclusive license to αvβ8 antibody patents.

Indications

Solid tumors (Phase 1)

Status note Anti-αvβ8 integrin monoclonal antibody that blocks activation of latent TGFβ. Phase 1 dose escalation study completed; program deprioritized — no additional patients will be enrolled.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	CRB-701
Lead indication	Oropharyngeal Carcinoma (OPC)
Lead phase	Phase 3
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07768189	Phase 3	Not yet recruiting	Sponsor	Corbus Pharmaceuticals Inc.	—	Oropharyngeal Carcinoma (OPC)	—
NCT06603844	Phase 1/2	Recruiting	Sponsor	Corbus Pharmaceuticals Inc.	—	Solid Tumor	—
NCT06265727	Phase 1/2	Recruiting	Sponsor	Corbus Pharmaceuticals Inc.	—	Solid Tumor, Adult	—
NCT07310901	Phase 1	Active, not recruiting	Sponsor	Corbus Pharmaceuticals Inc.	—	Obese But Otherwise Healthy Participants	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Corbus Pharmaceuticals Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Cormorant Asset Management	2,344,971	no change	1.13%	2026-08-14
OrbiMed Advisors	1,737,287	no change	0.31%	2026-08-14
Stonepine Capital	425,000	+41,538	3.03%	2026-08-17
ADAR1 Capital Management	421,787	+90,006	0.19%	2026-08-14
DAFNA Capital	107,773	+107,773	0.19%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

CRBP — Corbus Pharmaceuticals Holdings Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

CRBP — Corbus Pharmaceuticals Holdings Inc.